A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
Status:
Terminated
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to study the safety and effectiveness of ADXS11-001 when
combined with standard chemotherapy and radiation treatment for anal cancer. ADXS11-001 is an
investigational agent that is not approved by the FDA to treat anal cancer or any other
cancer.